Prostate cancer is
manageable
Knowing more with Decipher empowers you in your prostate cancer journey
Decipher genomic testing reveals the underlying biology of your tumor, providing clarity and confidence in treatment planning
More Accurate Risk Stratification
All patients with localized disease can benefit from Decipher
Decipher Prostate is a genomic classifier that stratifies patients by risk of prostate cancer progression. Physicians use Decipher to help determine which patients may be safe for less intensive treatment approaches and which may need additional or more intensive treatment.
Tumor Subtyping to Optimize Therapy
Patients with T1 or muscle-invasive bladder cancer can benefit from Decipher Bladder
Decipher Bladder classifies bladder cancer tumors by molecular subtype. Physicians use Decipher Bladder to identify which patients are at highest risk of upstaging at radical cystectomy and which are most likely to benefit from neoadjuvant chemotherapy.
Extensively Validated
Decipher has been validated in 75+ studies across more than 60,000 patients for metastasis, prostate cancer-specific mortality, and overall survival.
Latest News
- Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
- New Data to Be Shared at Asco 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
- Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer